10x Genomics Begins Commercial Shipments Of Chromium GEM-X Products
Portfolio Pulse from Benzinga Newsdesk
10x Genomics, Inc. (NASDAQ:TXG) has started commercial shipments of its next-generation single cell technology products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, powered by the new GEM-X technology. GEM-X offers enhanced performance, including up to two times more gene detection, a two-fold increase in cells captured per channel, more than two-fold reduction in cost per cell, and improved data quality. These advancements are expected to significantly benefit research in single cell and spatial biology.
March 13, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics begins shipping GEM-X powered products, promising significant advancements in single cell analysis with improved performance and cost efficiency.
The launch of GEM-X technology by 10x Genomics represents a significant advancement in the field of single cell and spatial biology, offering substantial improvements in gene detection, scalability, and cost efficiency. These enhancements are likely to attract more customers and potentially increase the company's market share in the biotechnology sector. The positive reception from the scientific community and the anticipated benefits to research could lead to increased sales and potentially a positive impact on TXG's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100